> top > docs > PubMed:25537159 > annotations

PubMed:25537159 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-163 Sentence denotes A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
T2 164-175 Sentence denotes BACKGROUND:
T3 176-232 Sentence denotes Chemotherapy is standard neoadjuvant treatment of LA BC.
T4 233-289 Sentence denotes Patients with HER2-positive BC require targeted therapy.
T5 290-490 Sentence denotes Trastuzumab and pertuzumab, which target HER2, with chemotherapy are approved as neoadjuvant therapy, however, treatments with different mechanisms of action might provide a broader range of activity.
T6 491-677 Sentence denotes In this study we evaluated the efficacy and safety of the irreversible ErbB family blocker afatinib, versus trastuzumab or lapatinib in the neoadjuvant treatment of HER2-positive, LA BC.
T7 678-699 Sentence denotes PATIENTS AND METHODS:
T8 700-982 Sentence denotes Treatment-naive, HER2-positive BC patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to daily afatinib (50 mg), lapatinib (1500 mg), or weekly trastuzumab (4 mg/kg loading dose, then 2 mg/kg/wk) for 6 weeks until surgery or follow-up neoadjuvant treatment.
T9 983-1105 Sentence denotes The primary end point was objective response rate according to Response Evaluation Criteria in Solid Tumors (version 1.0).
T10 1106-1114 Sentence denotes RESULTS:
T11 1115-1274 Sentence denotes Recruitment was stopped early because of slow patient enrollment; 29 patients were randomized to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11).
T12 1275-1368 Sentence denotes Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients.
T13 1369-1492 Sentence denotes Eleven patients had stable disease (best response); 1 lapatinib- and 1 trastuzumab-treated patient had progressive disease.
T14 1493-1736 Sentence denotes All 10 afatinib-treated patients experienced drug-related adverse events (commonly diarrhea, dermatitis acneiform, and paronychia) versus 6 of 8 lapatinib- (diarrhea and rash) and 5 of 11 trastuzumab-treated patients (vomiting and arthralgia).
T15 1737-1748 Sentence denotes CONCLUSION:
T16 1749-1987 Sentence denotes Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive BC, with a safety profile consistent with epidermal growth factor receptor tyrosine kinase inhibitors.
T1 0-163 Sentence denotes A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
T2 164-175 Sentence denotes BACKGROUND:
T3 176-232 Sentence denotes Chemotherapy is standard neoadjuvant treatment of LA BC.
T4 233-289 Sentence denotes Patients with HER2-positive BC require targeted therapy.
T5 290-490 Sentence denotes Trastuzumab and pertuzumab, which target HER2, with chemotherapy are approved as neoadjuvant therapy, however, treatments with different mechanisms of action might provide a broader range of activity.
T6 491-677 Sentence denotes In this study we evaluated the efficacy and safety of the irreversible ErbB family blocker afatinib, versus trastuzumab or lapatinib in the neoadjuvant treatment of HER2-positive, LA BC.
T7 678-699 Sentence denotes PATIENTS AND METHODS:
T8 700-982 Sentence denotes Treatment-naive, HER2-positive BC patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to daily afatinib (50 mg), lapatinib (1500 mg), or weekly trastuzumab (4 mg/kg loading dose, then 2 mg/kg/wk) for 6 weeks until surgery or follow-up neoadjuvant treatment.
T9 983-1105 Sentence denotes The primary end point was objective response rate according to Response Evaluation Criteria in Solid Tumors (version 1.0).
T10 1106-1114 Sentence denotes RESULTS:
T11 1115-1274 Sentence denotes Recruitment was stopped early because of slow patient enrollment; 29 patients were randomized to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11).
T12 1275-1368 Sentence denotes Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients.
T13 1369-1492 Sentence denotes Eleven patients had stable disease (best response); 1 lapatinib- and 1 trastuzumab-treated patient had progressive disease.
T14 1493-1736 Sentence denotes All 10 afatinib-treated patients experienced drug-related adverse events (commonly diarrhea, dermatitis acneiform, and paronychia) versus 6 of 8 lapatinib- (diarrhea and rash) and 5 of 11 trastuzumab-treated patients (vomiting and arthralgia).
T15 1737-1748 Sentence denotes CONCLUSION:
T16 1749-1987 Sentence denotes Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive BC, with a safety profile consistent with epidermal growth factor receptor tyrosine kinase inhibitors.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
25537159-0#135#139#gene2064 135-139 gene2064 denotes HER2
25537159-0#149#162#diseaseC0006142 149-162 diseaseC0006142 denotes breast cancer
25537159-0#149#162#diseaseC0678222 149-162 diseaseC0678222 denotes breast cancer
135#139#gene2064149#162#diseaseC0006142 25537159-0#135#139#gene2064 25537159-0#149#162#diseaseC0006142 associated_with HER2,breast cancer
135#139#gene2064149#162#diseaseC0678222 25537159-0#135#139#gene2064 25537159-0#149#162#diseaseC0678222 associated_with HER2,breast cancer

wangzhuo19_800

Id Subject Object Predicate Lexical cue
T1 290-301 CI denotes Trastuzumab
T2 306-316 CI denotes pertuzumab
T3 582-590 CI denotes afatinib
T4 599-610 CI denotes trastuzumab
T5 614-623 CI denotes lapatinib
T6 820-828 CI denotes afatinib
T7 838-847 CI denotes lapatinib
T8 869-880 CI denotes trastuzumab
T9 1212-1220 CI denotes afatinib
T10 1231-1240 CI denotes lapatinib
T11 1253-1264 CI denotes trastuzumab
T12 1308-1316 CI denotes afatinib
T13 1321-1330 CI denotes lapatinib
T14 1339-1350 CI denotes trastuzumab
T15 1423-1432 CI denotes lapatinib
T16 1440-1451 CI denotes trastuzumab
T17 1500-1508 CI denotes afatinib
T18 1638-1647 CI denotes lapatinib
T19 1681-1692 CI denotes trastuzumab
T20 1749-1757 CI denotes Afatinib
T21 1816-1827 CI denotes trastuzumab
T22 1832-1841 CI denotes lapatinib
T24 226-231 DP denotes LA BC
T25 247-263 DP denotes HER2-positive BC
T26 135-162 DP denotes HER2-positive breast cancer
T27 656-676 DP denotes HER2-positive, LA BC
T28 717-742 DP denotes HER2-positive BC patients
T29 1871-1887 DP denotes HER2-positive BC